WA
KROS icon

WPG Advisers’s Keros Therapeutics KROS Stock Holding History

WPG Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257 Hold
24
– – ﹤0.01% 1489
2026
Q1 		$265 Hold
24
– – ﹤0.01% 1417
2025
Q4 		$489 Hold
24
– – ﹤0.01% 1384
2025
Q3 		$380 Hold
24
– – ﹤0.01% 1392
2025
Q2 		$320 Hold
24
– – ﹤0.01% 1386
2025
Q1 		$245 Buy
+24
New +$279 ﹤0.01% 1396

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

WPG Advisers's KROS Position: Q2 2026 in Review

WPG Advisers held its Keros Therapeutics (KROS) position steady in Q2 2026 at 24 shares worth $257. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

WPG Advisers first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $489 in Q4 2025. 35 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • WPG Advisers held 24 shares of Keros Therapeutics worth $257 as of Q2 2026.
  • WPG Advisers left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1489 holding.
  • WPG Advisers first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • WPG Advisers's Keros Therapeutics position peaked at $489 in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.